# Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily

> **NCT03067415** · PHASE2 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 98 (estimated)

## Conditions studied

- Glaucoma, Primary Open Angle
- Ocular Hypertension

## Interventions

- **DRUG:** D565H(Latanoprost 25㎍/㎖)
- **DRUG:** D565(Latanoprost 50㎍/㎖)

## Key facts

- **NCT ID:** NCT03067415
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-30
- **Primary completion:** 2017-09-10
- **Final completion:** 2017-09-30
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03067415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03067415, "Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03067415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*